Skip to content

Advertisement

  • Research article
  • Open Access
  • Open Peer Review

Impact of comorbidities and use of common medications on cancer and non-cancer specific survival in esophageal carcinoma

  • 5,
  • 2,
  • 1,
  • 1,
  • 3,
  • 4 and
  • 1Email author
BMC Cancer201515:111

https://doi.org/10.1186/s12885-015-1095-2

  • Received: 29 October 2014
  • Accepted: 20 February 2015
  • Published:
Open Peer Review reports

Abstract

Background

Chronic comorbidities and some of the commonly-used medications are thought to affect cancer patients’ outcomes, but their relative impact on esophageal carcinoma (EC) has not been well studied. The purpose of the study was to identify the chronic comorbidities and/or commonly-used medications that impact EC patient survival.

Methods

A total of 1174 EC patients treated with chemoradiotherapy (CRT) with or without surgery in one institution from 1998 to 2012 were retrospectively included. Seven kinds of frequently occurring chronic comorbidities and 18 types of regularly-taken medications were obtained from medical records. Since it is expected prognostic factors have different effects between surgery patients and non-surgery patients, the impact value of all variables and the corresponding interactions with surgery on survival were evaluated in Cox proportional hazards regression model. Overall mortality, EC-specific mortality and non EC-specific mortality were endpoints.

Results

We found that atrial fibrillation was the only comorbidity that showed a significant impact on non-EC specific survival for all patients (HR 1.72, P = 0.03), whereas hypothyroidism was the only comorbidity that was evaluated as an independent predictive factor for overall survival (OS) (HR 0.59, P = 0.02) and EC-specific survival (HR 0.62, P = 0.05), but this association was seen only in the non-surgical patients. No other medications were found to have a significant impact for OS, EC-specific survival or non-EC specific survival in multivariable analysis.

Conclusions

Our data indicate that certain comorbidities rather than medication use affect EC-specific survival or non EC-specific survival in EC patients treated with CRT with or without surgery. Comorbidity information may better guide individual treatment in EC.

Keywords

  • Esophageal carcinoma
  • Comorbidity
  • Medication
  • Survival

Background

Concurrent chemoradiotherapy (CRT) followed by surgery is widely accepted as the standard treatment for locally advanced esophageal carcinoma (EC). However, there is still a portion of patients being excluded from this curative combined therapy mainly because of the poor performance status due to comorbidities [1]. Until now, how these common comorbidities influence EC patient survival is known to a limited degree. In a retrospective study of a large Esophagogastric Cancer Registry, postoperative mortality was found to increase in patients of advanced age and with greater comorbidity [2]. By contrast, another report recently revealed that there was no increased risk for mortality in EC patients with diabetes or other common comorbidities selected for surgery [3]. So far, the limited prior studies focused mainly on EC patients treated with surgery and with inconsistent results. Even less is known on how these comorbidities affect clinical outcomes for patients treated without surgery.

For patients with certain comorbidities, the medications used for treating these ailments are inevitably used throughout the treatment course. Recently, the importance of the medication information has attracted more and more attention. Firstly, a key advantage for analyzing medication use is the objectivity and better accuracy in assessing a patient’s underlying health conditions than past medical history documentation. Second, the dose of the medications may provide a better perspective on the severity of the comorbid condition. Third, the use of some medications has already been reported to be associated with the risk and/or therapy response of EC [4-6]. However the degree these drugs affect prognosis of esophageal cancer is not known. Furthermore, the relative impact that comorbid disease has on prognosis as compared to the use of certain medications for the specific ailments is also not well understood.

The purpose of our study was to understand the relative impact that comorbid diseases and medication use have on the patients’ survival. We evaluated how these two factors influenced EC-specific death and non EC-specific death in a large cohort of EC patients treated with CRT with or without surgery.

Methods

Patient selection

All patients had histologically proven primary esophageal carcinoma and treated with concurrent CRT with or without esophagectomy. A total of 1174 patients (560 and 614 patients with and without esophagectomy, respectively) treated in our institution from January 1998 to April 2012 were included for this analysis. This study was approved by the institutional review board of The University of Texas MD Anderson Cancer Center and was performed in accordance with the Declaration of Helsinki [7].

Evaluations and interventions

Staging and restaging was done according to the 6th (2002) edition of the American Joint Committee on Cancer (AJCC) staging manual for esophageal carcinoma. Patients were treated with concurrent CRT with or without induction chemotherapy and following esophagectomy. Radiation was delivered with 3-dimensional conformal radiation (3D-CRT), intensity-modulated radiation (IMRT), or proton beam therapy. The typical radiation dose was 50.4 Gy in 28 fractions. All patients received platin- or taxane-based chemotherapy with fluorouracil. CRT response was evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST) system at 0–3 months after the completion of CRT. Esophagectomy was approved by the thoracic multidisciplinary group according the re-evaluation after CRT, and was performed 4–8 weeks after CRT completion.

Data collection

Medical records were reviewed for baseline characteristics, preexisting chronic comorbidities, preexisting regularly-taken medications, treatment modalities, tumor control and patients’ survival outcomes. According to the past medical history record, the preexisting chronic comorbidities including the following 4 most frequently occurring groups: (1) hypertension; (2) cardiovascular disease (coronary artery disease [CAD] and atrial fibrillation [AF] (any types included, intermittent or persistent)); (3) pulmonary disease (chronic obstructive pulmonary disease [COPD] and asthma) and (4) metabolic diseases (diabetes and hypothyroidism). Other medical comorbidities which included less than 2.5% (30) of the patients were not included in the analysis, such as cerebrovascular disease, gout, hyperthyroidism, anemia and prostatic hypertrophy.

In total, 12 kinds of medications used for the above comorbidities were also recorded: (1) anti-hypertensive drugs (angiotensin-converting enzyme inhibitor/angiotensin receptor blockers (ACEi/ARB), beta-blocker, calcium channel antagonist, alpha-1-adrenoceptor blocker and diuretic) (2) cardiovascular drugs (cardiac glycoside and coronary vasodilator), (3) bronchodilators, (4) hypoglycemic agents (insulin, sulfonylureas, biguanide) and (5) levothyroxine. Other antiarrhythmic drugs except beta-blocker and cardiac glycoside, and other hypoglycemic drugs were not included because the frequency was less than 2.5% of the patients.

In addition, 6 kinds of other medications, frequently used by this cohort of the patients, were also included: (1) antacids, (2) non-steroidal anti-inflammatory drugs (NSAIDs), (3) antihyperlipidemics (statins and other lipid-regulating agents), (4) antithrombotics and (5) antidepressants. Since all the patients recorded as having hypothyroidism also regularly took levothyroxine, hypothyroidism/levothyroxine was considered one variable in analysis.

Outcome definition

Local/regional failure was defined as the persistence or recurrence of the primary tumor and regional lymph nodes, while distant failure was defined as metastasis to any site beyond the primary tumor and regional lymph nodes. OS, EC-specific survival and non EC-specific survival were defined as the time from the end of CRT to any cause of death, either due to esophageal carcinoma or any cause of death other than esophageal carcinoma, respectively. Since the date record of CRT end is missing for one patient treated in 1998, leaving 1173 patients for survival analysis.

Statistical analysis

The distribution of each categorical variable was summarized in terms of its frequencies and percentages. Fisher’s exact texts were used to assess measures of association in frequency tables. Survival curves were obtained with the Kaplan-Meier method and compared with log-rank tests. The Cox proportional hazards regression model was used to evaluate the ability of patient prognostic variables or surgery effect to predict survival. Since receipt of surgery has been recognized as a major prognostic factor for loco-regional EC and it is expected that the prognostic factors would have different impacts on survival between surgery patients and non-surgery patients, the interaction term of each prognostic factor and surgery is included for each variable in the univariable analysis. The variables with either potentially significant main effect or the interaction term (P < 0.10) were selected and included in the multivariable mode for OS, EC-specific survival and non EC-specific survival. A P value less than 0.05 was considered statistically significant in multivariable analysis. For each significant interaction term in the multivariate model, it indicates that the corresponding variable affect survival differently in surgery and non-surgery patient. Hence, the hazard rate (HR) for death, 95% confidence interval [CI] and P value of the variable were further calculated for surgery and non-surgery patients respectively. All computations were carried out in SAS version 9.3. (SAS Institute, Cary, NC) and all statistical tests were 2-sided.

Results

Patient characteristics, comorbidities and medications

Baseline characteristics of the 1174 EC patients in our cohort are listed in Table 1. The frequencies of the major comorbidities and medications are presented in Table 2. The most prevalent comorbidity was hypertension, followed by diabetes, CAD, hypothyroidism, COPD and asthma. Antacid, NSAIDS, statins, ACEi/ARB and beta-blocker were the top five frequently used medications.
Table 1

Patient and tumor characteristics

Characteristics

Value or No. of patients (%)

Age at diagnosis (years)

 

  Median (Range)

64 (20-91)

Gender

 

  Female

182(15.5)

  Male

992(84.5)

Race

 

  White

1028(87.6)

  Non-white

146(12.4)

BMI

 

  ≤25

285(24.3)

  >25

704(60.0)

  Not applicable

185(15.7)

KPS

 

   70

117(10.0)

  80-100

1057(90.0)

Heavy alcohol use history

250(21.3)

Smoking at diagnosis

248 (21.1)

   No

924(78.7)

   Yes

250(21.3)

Second malignancy

186(15.8)

Tumor location

 

  Proximal/ Middle

159(13.5)

  Distal

1015(86.5)

Tumor histology

 

  ADE

914(77.9)

  SCC

237(20.2)

  Others

23(1.9)

Tumor differentiation

 

  Well/ Moderate

517(44.0)

  Poor

644(54.9)

  Not applicable

13(1.1)

Tumor length (cm)

 

  Median(Range)

5(0.4-20.0)

Clinical stage

 

  I-II

432(36.8)

  III-IV

714(60.8)

  Not applicable

28(2.4)

Induction chemotherapy

468 (40.0)

Radiation modality

 

  3DCRT

469(39.9)

  IMRT/Proton

705(60.1)

   Surgery

560(47.7)

KPS: Karnofsky performance scores; BMI: body mass index; ADE: adenocarcinoma; SCC: squamous cell carcinoma; 3DCRT: 3-dimensional conformal radiation; IMRT: intensity-modulated radiation.

Table 2

Univariate survival analysis of comorbidities, medications and their interactions with surgery

  

Overall survival

EC-specific survival

Non-EC specific survival

Variables

No. (%)

HR(95% CI)1

P 1

HR(95% CI)1

P 1

HR(95% CI)1

P 1

Hypertension

620(52.8)

0.92(0.76-1.11)

0.38

0.92(0.73-1.16)

0.47

0.91(0.66-1.26)

0.57

Interaction with surgery

 

1.18(0.88-1.60)

0.27

1.00(0.69-1.45)

1.00

1.67(0.99-2.81)

0.05

CAD

184(15.7)

1.00(0.80-1.25)

0.99

0.88(0.66-1.16)

0.36

1.26(0.86-1.84)

0.24

Interaction with surgery

 

1.05(0.67-1.66)

0.83

0.94(0.51-1.70)

0.83

1.29(0.63-2.64)

0.49

AF

63(5.4)

1.23(0.89-1.71)

0.22

0.84(0.53-1.34)

0.48

2.19(1.36-3.51)

<0.01

Interaction with surgery

 

0.63(0.28-1.44)

0.28

0.57(0.17-1.95)

0.37

0.68(0.22-2.05)

0.49

COPD

65(5.5)

1.14(0.80-1.62)

0.47

0.69(0.40-1.18)

0.17

2.22(1.37-3.59)

<0.01

Interaction with surgery

 

0.66(0.29-1.52)

0.33

0.66(0.19-2.31)

0.51

0.68(0.22-2.08)

0.50

Asthma

36(3.1)

1.09(0.68-1.75)

0.71

0.79(0.41-1.53)

0.48

1.81(0.92-3.56)

0.09

Interaction with surgery

 

1.38(0.59-3.22)

0.46

1.80(0.59-5.46)

0.30

0.93(0.25-3.56)

0.92

Diabetes

193(16.4)

1.10(0.87-1.40)

0.43

1.13(0.85-1.51)

0.39

1.04(0.68-1.61)

0.84

Interaction with surgery

 

0.98(0.64-1.50)

0.92

0.72(0.42-1.26)

0.25

1.59(0.81-3.15)

0.18

Hypothyroidism/levothyroxine

102(8.7)

0.59(0.42-0.83)

<0.01

0.52(0.33-0.80)

<0.01

0.74(0.43-1.29)

0.29

Interaction with surgery

 

2.26(1.32-3.86)

<0.01

2.27(1.14-4.52)

0.02

2.21(0.94-5.21)

0.07

ACEi/ARB

350(29.8)

0.99(0.81-1.21)

0.95

0.94(0.73-1.20)

0.60

1.10(0.78-1.56)

0.58

Interaction with surgery

 

1.06(0.76-1.47)

0.72

0.97(0.64-1.46)

0.87

1.28(0.74-2.22)

0.38

beta-Blocker

217(18.5)

0.95(0.76-1.18)

0.65

1.05(0.81-1.36)

0.73

0.74(0.49-1.12)

0.16

Interaction with surgery

 

1.07(0.71-1.61)

0.73

0.71(0.42-1.21)

0.21

2.29(1.18-4.43)

0.01

Calcium antagonist

172(14.7)

1.01(0.79-1.30)

0.92

1.05(0.78-1.42)

0.73

0.94(0.60-1.48)

0.79

Interaction with surgery

 

1.24(0.82-1.86)

0.31

1.06(0.63-1.77)

0.82

1.63(0.82-3.23)

0.16

alpha-1-Adrenoceptor blocker

105(8.9)

1.19(0.90-1.58)

0.23

1.08(0.76-1.55)

0.67

1.45(0.90-2.32)

0.12

Interaction with surgery

 

1.12(0.67-1.87)

0.66

1.05(0.54-2.04)

0.89

1.20(0.54-2.70)

0.65

Diuretic

200(17.0)

1.01(0.80-1.26)

0.96

0.93(0.7-1.24)

0.63

1.13(0.77-1.66)

0.53

Interaction with surgery

 

1.18(0.79-1.77)

0.42

1.27(0.77-2.08)

0.35

1.07(0.53-2.16)

0.85

Cardiac glycoside

48(4.1)

1.04(0.72-1.51)

0.83

0.67(0.38-1.17)

0.16

1.83(1.11-3.04)

0.02

Interaction with surgery

 

2.09(0.94-4.62)

0.07

2.41(0.77-7.51)

0.13

1.82(0.59-5.60)

0.30

Coronary vasodilator

33(2.8)

0.61(0.36-1.04)

0.07

0.67(0.35-1.25)

0.21

0.50(0.19-1.36)

0.18

Interaction with surgery

 

1.66(0.66-4.15)

0.28

0.69(0.15-3.18)

0.63

3.89(1.02-14.88)

0.05

Bronchodilator

33(2.8)

1.34(0.84-2.15)

0.22

0.53(0.22-1.27)

0.15

3.35(1.89-5.93)

<0.01

Interaction with surgery

 

0.73(0.27-1.98)

0.53

2.05(0.54-7.74)

0.29

0.21(0.03-1.62)

0.13

Insulin

37(3.2)

0.81(0.47-1.37)

0.43

0.66(0.32-1.32)

0.24

1.17(0.52-2.65)

0.71

Interaction with surgery

 

1.87(0.67-5.25)

0.23

1.27(0.27-6.07)

0.76

2.76(0.67-11.31)

0.16

Sulfonylurea

75(6.4)

1.34(0.95-1.88)

0.09

1.53(1.04-2.26)

0.03

0.94(0.46-1.93)

0.87

Interaction with surgery

 

0.71(0.37-1.37)

0.31

0.35(0.13-0.92)

0.03

2.02(0.73-5.59)

0.18

Biguanide

104(8.9)

0.99(0.70-1.40)

0.97

1.11(0.75-1.65)

0.60

0.74(0.36-1.51)

0.41

Interaction with surgery

 

0.85(0.48-1.49)

0.57

0.62(0.31-1.26)

0.19

1.62(0.60-4.35)

0.34

Antacid

657(56.0)

0.74(0.62-0.89)

<0.01

0.79(0.63-0.99)

0.04

0.67(0.48-0.92)

0.01

Interaction with surgery

 

1.25(0.92-1.69)

0.15

1.21(0.84-1.76)

0.31

1.30(0.77-2.19)

0.30

NSAIDs

507(43.2)

1.10(0.92-1.33)

0.30

1.06(0.84-1.33)

0.63

1.19(0.86-1.64)

0.30

Interaction with surgery

 

0.90(0.66-1.22)

0.50

0.89(0.61-1.29)

0.54

0.94(0.55-1.6)

0.82

Statins

400(34.1)

0.84(0.69-1.02)

0.08

0.81(0.64-1.04)

0.09

0.87(0.62-1.23)

0.43

Interaction with surgery

 

1.19(0.86-1.64)

0.30

1.05(0.70-1.56)

0.81

1.53(0.89-2.66)

0.13

Variables

NO. (%)

HR(95%CI) 1

P 1

HR(95%CI) 1

P 1

HR(95%CI) 1

P 1

Other lipid-regulating agents

60(5.1)

0.88(0.55-1.41)

0.60

1.08(0.64-1.82)

0.77

0.46(0.15-1.45)

0.19

Interaction with surgery

 

0.75(0.36-1.56)

0.45

0.41(0.16-1.07)

0.07

2.53(0.64-10.06)

0.19

Antithrombotic

119(10.1)

0.99(0.75-1.30)

0.94

0.86(0.61-1.22)

0.40

1.29(0.83-2.00)

0.25

Interaction with surgery

 

1.03(0.59-1.80)

0.93

0.91(0.43-1.93)

0.80

1.19(0.51-2.78)

0.68

Antidepressant

215(18.3)

0.99(0.79-1.24)

0.92

0.98(0.74-1.30)

0.91

1.01(0.67-1.50)

0.97

Interaction with surgery

 

1.06(0.72-1.57)

0.76

0.89(0.55-1.47)

0.66

1.43(0.75-2.73)

0.27

1Other factors analyzed in univariate analysis include: age, sex, race, BMI, heavy alcohol use history, smoking at diagnosis, second malignancy, Karnofsky performance scores, tumor histology, tumor location, tumor differentiation, clinical stage, induction chemotherapy, radiation modality and their interactions with surgery.

EC: esophageal carcinoma; HR: hazard rate; CI: confidence interval; CAD: coronary artery disease; AF: atrial fibrillation; COPD: chronic obstructive pulmonary disease; ACEi: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; NSAIDs: non-steroidal anti-inflammatory drugs.

Impact of comorbidities and medications on outcomes

The median follow-up for the whole cohort was 25 months (3 to 186 months) with a 5y-OS of 38%. Besides the comorbidities and medications, the impact value of age, sex, race, body mass index (BMI), heavy alcohol use history, smoke at diagnosis, second malignancy, Karnofsky performance scores, tumor histology, tumor location, tumor differentiation, clinical stage, induction chemotherapy, radiation modality and their interactions with surgery were all tested in univariate analysis. Other factors which showed a significant impact on OS, EC-specific survival or non-EC specific survival in univariate analysis were listed in the footnote of Table 2. All the parameters included in the multivariate analysis were listed in the footnote of Table 3. After adjusting for patients’ baseline characteristics, AF was the only comorbidity that showed a significant impact on non-EC specific survival in both univariable (Table 2, Figure 1) and multivariable analysis (Table 3). For OS and EC-specific survival, hypothyroidism/levothyroxine was also the only significant factor in both univariable and multivariable analysis, with a significant interaction with surgery. It had a significant impact on OS (HR 0.59, 95% CI 0.38–0.93, P = 0.02) and EC-specific survival (HR 0.62, 95% CI 0.38–1.01, P = 0.05) for non-surgery patients but not for the surgery patients.
Table 3

Multivariate survival analysis of comorbidities, medications and their interactions with surgery

 

Overall survival

EC-specific survival

Non-EC specific survival

Variables

HR(95% CI)1

P 1

HR(95% CI)2

P 2

HR(95% CI)3

P 3

Hypertension

-

-

-

-

0.94(0.66-1.33)

0.71

Interaction with surgery

-

-

-

-

1.36(0.77-2.41)

0.29

AF

-

-

-

-

1.72(1.07-2.77)

0.03

Interaction with surgery

-

-

-

-

-

-

COPD

-

-

-

-

1.43(0.88-2.38)

0.15

Interaction with surgery

-

-

-

-

-

-

Asthma

-

-

-

-

1.42(0.75-2.70)

0.28

Interaction with surgery

-

-

-

-

-

-

Hypothyroidism/ levothyroxine

0.59(0.38-0.93)

0.02

0.62(0.38-1.01)

0.05

0.78(0.44-1.37)

0.39

Interaction with surgery

2.04(1.09-3.83)

0.03

2.20(1.03-4.69)

0.04

1.50(0.61-3.69)

0.38

beta-Blocker

-

-

-

-

0.70(0.45-1.07)

0.10

Interaction with surgery

-

-

-

-

2.26(1.09-4.68)

0.03

Cardiac glycoside

1.50(0.92-2.44)

0.10

-

-

1.31(0.78-2.20)

0.30

Interaction with surgery

1.19(0.48-2.96)

0.71

-

-

-

-

Coronary vasodilator

0.93(0.54-1.61)

0.80

-

-

0.45(0.16-1.28)

0.13

Interaction with surgery

-

-

-

-

2.92(0.72-11.97)

0.13

Bronchodilator

-

-

-

-

1.89(0.98-3.62)

0.06

Interaction with surgery

-

-

-

-

-

-

Sulfonylurea

1.15(0.81-1.65)

0.43

1.28(0.79-2.07)

0.32

-

-

Interaction with surgery

-

-

0.49(0.18-1.36)

0.17

-

-

Antacid

0.94(0.79-1.12)

0.47

0.92(0.75-1.13)

0.41

0.80(0.61-1.05)

0.11

Interaction with surgery

-

-

-

-

-

-

Statin

0.92(0.76-1.11)

0.38

0.87(0.70-1.07)

0.19

-

-

Interaction with surgery

-

-

-

-

-

-

Other lipid-regulating agents

-

-

0.98(0.56-1.71)

0.94

-

-

Interaction with surgery

-

-

0.66(0.24-1.77)

0.40

-

-

1Adjusted for the interactions of age, race, tumor histology and tumor location with surgery, BMI, smoking at diagnosis, Karnofsky performance scores, tumor location, clinical stage, radiation modality and surgery for overall survival.

2Adjusted for the interactions of race, age, tumor histology and tumor location with surgery, sex, race, age, smoking at diagnosis, tumor histology, tumor length, tumor differentiation, clinical stage, radiation modality and surgery for EC-specific death free survival.

3Adjusted for the interactions of tumor histology and tumor location with surgery, age, Karnofsky performance scores, tumor histology, induction chemotherapy, radiation modality and surgery for non-EC specific death free survival.

EC: esophageal carcinoma; HR: hazard rate; CI: confidence interval; AF: atrial fibrillation; COPD: chronic obstructive pulmonary disease.

Figure 1
Figure 1

Non-esophageal carcinoma specific survival for patients with and without atrial fibrillation.

To better interpret the significant interaction of hypothyroidism/levothyroxine and surgery for OS and EC-specific survival, the survival curves stratified by hypothyroidism/levothyroxine and surgery were further presented in Figure 2A and B. The 5 year OS (45% vs. 25%, P = 0.003) and EC-specific survival (62% vs. 38%, P = 0.004) for patients with hypothyroidism/levothyroxine was significant higher than those without hypothyroidism/levothyroxine for non-surgery patients but not for surgery patients (P > 0.05).
Figure 2
Figure 2

Survival stratified by hypothyroidism and surgery status for patients with esophageal carcinoma. A: Overall survival, B: Esophageal carcinoma-specific survival.

Characteristics difference between patients with/without AF and hypothyroidism/levothyroxine

Since AF and hypothyroidism/levothyroxine were found to significantly impact patients’ survival, we compared the difference of the clinico-pathologic characteristics between patients with and without AF (Table 4) and hypothyroidism/levothyroxine (Table 5), respectively. There were more patients who are older than 64 yrs (P < 0.01), had no surgery (P < 0.01), treated with IMRT/proton therapy (P < 0.01), without a complete CRT response (P = 0.02) and had a lower distant failure rate (P = 0.01) in the AF group than in non-AF group. No difference was observed on other clinico-pathologic characteristics between the two groups (Table 4).
Table 4

Characteristics of esophageal carcinoma patients with or without Atrial fibrillation

  

Atrial fibrillation

P 1

Variables

 

No

Yes

 

Sex

Female

174(15.7%)

8(12.7%)

0.72

 

Male

937(84.3%)

55(87.3%)

 

Race

non-White

143(12.9%)

3(4.8%)

0.07

 

White

968(87.1%)

60(95.2%)

 

BMI

≤25

271(29.1%)

14(24.1%)

0.45

 

>25

660(70.9%)

44(75.9%)

 

Age (years)

≤64

601(54.1%)

12(19%)

<0.01

 

>64

510(45.9%)

51(81%)

 

Heavy alcohol use history

No

868(78.3%)

54(85.7%)

0.21

 

Yes

241(21.7%)

9(14.3%)

 

Smoke at diagnosis

No

869(78.5%)

53(84.1%)

0.34

 

Yes

238(21.5%)

10(15.9%)

 

KPS

≤70

107(9.6%)

10(15.9%)

0.13

 

>70

1004(90.4%)

53(84.1%)

 

Tumor histology

ADC

864(79.2%)

50(79.4%)

1.00

 

SCC

227(20.8%)

13(20.6%)

 

Tumor location

Upper/middle

152(13.7%)

7(11.1%)

0.71

 

Low

959(86.3%)

56(88.9%)

 

Tumor differentiation

Well/moderate

487(44.4%)

30(47.6%)

0.70

 

Poor

611(55.6%)

33(52.4%)

 

Tumor length (cm)

≤5

564(57.7%)

35(59.3%)

0.89

 

>5

414(42.3%)

24(40.7%)

 

Clinical stage

I-II

403(37.2%)

28(44.4%)

0.28

 

III-IV

680(62.8%)

35(55.6%)

 

Surgery

No

567(51%)

47(74.6%)

<0.01

 

Yes

544(49%)

16(25.4%)

 

Radiation modality

3DCRT

456(41%)

13(20.6%)

<0.01

 

IMRT/proton

655(59%)

50(79.4%)

 

Induction chemotherapy

No

662(59.6%)

44(69.8%)

0.11

 

Yes

449(40.4%)

19(30.2%)

 

CRT complete response

No

658(62.3%)

47(77%)

0.02

 

Yes

399(37.7%)

14(23%)

 

Chemotherapy after relapse

No

948 (85.3%)

56 (88.9%)

0.58

 

Yes

163 (14.7%)

7 (11.1%)

 

Local/regional failure rate

No

298(30.5%)

17(33.3%)

0.64

 

Yes

678(69.5%)

34(66.7%)

 

Distant failure rate

No

556(54.9%)

38(73.1%)

0.01

 

Yes

456(45.1%)

14(26.9%)

 

1Fisher exact test.

KPS: Karnofsky performance scores; BMI: body mass index; ADC: adenocarcinoma; SCC: squamous cell carcinoma; 3DCRT: 3-dimensional conformal radiation; IMRT: intensity-modulated radiation: CRT: chemoradiotherapy.

Table 5

Characteristics of esophageal carcinoma patients with or without hypothyroidism/levothyroxine

  

Hypothyroidism/Levothyroxine

P 1

Variables

 

No

Yes

 

Sex

Female

148(13.8%)

34(33.3%)

<0.01

 

Male

924(86.2%)

68(66.7%)

 

Race

non-White

131(12.2%)

15(14.7%)

0.44

 

White

941(87.8%)

87(85.3%)

 

BMI

≤25

262(29.1%)

23(25.8%)

0.62

 

>25

638(70.9%)

66(74.2%)

 

Age (years)

≤64

569(53.1%)

44(43.1%)

0.06

 

>64

503(46.9%)

58(56.9%)

 

Heavy alcohol use history

No

839(78.4%)

83(81.4%)

0.53

 

Yes

231(21.6%)

19(18.6%)

 

Smoke at diagnosis

No

830(77.6%)

92(91.1%)

<0.01

 

Yes

239(22.4%)

9(8.9%)

 

KPS

≤70

104(9.7%)

13(12.7%)

0.30

 

>70

968(90.3%)

89(87.3%)

 

AF

No

1013(94.5%)

98(96.1%)

0.65

 

Yes

59(5.5%)

4(3.9%)

 

Tumor histology

ADC

841(79.9%)

73(71.6%)

0.05

 

SCC

211(20.1%)

29(28.4%)

 

Tumor location

Upper/middle

140(13.1%)

19(18.6%)

0.13

 

Low

932(86.9%)

83(81.4%)

 

Tumor differentiation

Well/moderate

477(45.0%)

40(39.6%)

0.35

 

Poor

583(55.0%)

61(60.4%)

 

Tumor length (cm)

≤5

537(56.9%)

62(66.7%)

0.08

 

>5

407(43.1%)

31(33.3%)

 

Clinical stage

I-II

383(36.6%)

48(48.5%)

0.02

 

III-IV

664(63.4%)

51(51.5%)

 

Surgery

No

553(51.6%)

64(59.8%)

0.12

 

Yes

519(48.4%)

41(40.2%)

 

Radiation modality

3DCRT

430(40.1%)

39(38.2%)

0.75

 

IMRT/proton

642(59.9%)

63(61.8%)

 

Induction chemotherapy

No

638(59.5%)

68(66.7%)

0.17

 

Yes

434(40.5%)

34(33.3%)

 

CRT complete response

No

651(63.5%)

54(58.1%)

0.31

 

Yes

374(36.5%)

39(41.9%)

 

Chemotherapy after relapse

No

914(85.3%)

90(88.2%)

0.47

 

Yes

158(14.7%)

12(11.8%)

 

Local/regional failure rate

No

290(31.0%)

25(26.9%)

0.48

 

Yes

644(69.0%)

68(73.1%)

 

Distant failure rate

No

532(55.0%)

62(64.6%)

0.08

 

Yes

436(45.0%)

34(35.4%)

 

1Fisher exact test.

KPS: Karnofsky performance scores; BMI: body mass index; ADC: adenocarcinoma; SCC: squamous cell carcinoma; AF: atrial fibrillation; 3DCRT: 3-dimensional conformal radiation; IMRT: intensity-modulated radiation: CRT: chemoradiotherapy.

There were more patients who are female (P < 0.01), without smoke at diagnosis (P < 0.01), with squamous cell carcinoma (SCC) histology (P = 0.05) and earlier clinical stage (P = 0.02) in the hypothyroidism/levothyroxine group than in non-hypothyroidism/levothyroxine group. No difference was observed on other clinico-pathologic characteristics between the two groups (Table 5).

Discussion

In our retrospective study, by simultaneously analyzing the impact value of 7 kinds of frequently occurring comorbidities and 18 types of regularly-taken medications on EC patient survival, we identified that certain comorbidities (hypothyroidism and AF) but not specific medications that affected EC-specific survival or non-EC specific survival in a large EC cohort treated with CRT with or without surgery.

It is generally recognized that comorbidities may affect patients’ prognosis mainly by impacting the non-cancer specific survival [1]. In addition, patients with comorbidities are more likely to experience severe treatment toxicities and even treatment related death [8]. For example, AF, which remains one of the most frequent complications after esophagectomy, has been reported to be associated with the pre-existing AF and increased postoperative mortality by several studies [9,10]. In our study, we found that AF was an adverse prognostic factor on non-EC specific survival for all CRT treated patients regardless of whether they received surgery or not. Considering the significant impact of AF on the prognosis of EC, an improved management of pre-existing AF in EC patients before and during cancer treatments should be recommended.

Interestingly, preexisting hypothyroidism was a significant protective factor for OS in non-surgical patients, possibly by affecting EC-specific death, since it showed no impact on non-EC specific survival in our analysis. Although the impact of hypothyroidism and human cancer has been a controversial issue [11,12], some recent data suggests that it is associated with a good prognosis of certain human cancers (head and neck, lung and renal cancers) [12-14]. Our study is the first to make this association for EC. We also found that patients with hypothyroidism tended to have earlier clinical stage disease than euthyroid patients, which was also observed for breast cancer patients [15]. The underlying mechanisms that have been proposed for the role of hypothyroidism in cancer are mainly through interfering the process of cell proliferation and apoptosis, since hypothyroidism is characterized by reduced production of thyroid hormone [16]. In animal models, thyroid hormone can stimulate tumor growth and metastasis, whereas hypothyroidism shows the opposite effects [17,18]. While to date, there is no specific study determining the mechanism by which hypothyroidism affect the prognosis of EC. It is unclear why the survival benefit of hypothyroidism was not seen for surgical patients. This observation will need confirmation in future studies.

There have been a number of reports showing that certain medications have an impact on EC. Biguanide (metformin), statins and NSAIDs (aspirin) have been reported to be associated with a clinically reduced EC incidence [6,19] and have an anti-tumor effect in EC cells [20-22]. Recently, a retrospective study showed that metformin use is associated with an increased CRT response in esophageal adenocarcinoma, but no benefit of metformin was observed for OS [4]. In our analysis, we could not identify a single medication effect on patient survival in EC. Although the survival benefit of certain drugs has been reported in some other human cancers [23,24], the recognized heterogeneity among the various studies [25] and the survival influence of certain drugs could be cancer-specific. To date, there are not reports that support the survival influence of any medications on EC patients.

The limitations of our study relate to the retrospective collection of comorbid information from the medical records elicited from physicians’ clinical evaluations, which may underestimate the existence of certain comorbidities if they were not asked or were not willingly provided by the patients. Second, it is important to note that the prevalence of certain comorbidities and medications can affect the statistical power to detect their impact on patient survival. Thus, the lack of the statistical significance for a certain variable with low prevalence should be interpreted with caution. Third, although our data does corroborate previously published studies supporting the protective role of hypothyroidism in certain types of human cancers, we can’t exclude the influence of levothyroxine on EC prognosis in our study, as all the patients with hypothyroidism also took levothyroxine. In addition, there is also a possibility that patients may take levothyroxine due to reasons other than hypothyroidism. Further studies are needed to better clarify the roles of hypothyroidism and levothyroxine on EC prognosis in different cohort of EC patients.

Conclusion

In conclusion, despite the growing evidence that some medications and/or their underlying comorbidities predict patients’ prognosis in some human cancers, certain comorbidities (hypothyroidism and AF) rather than commonly-used medications affect patient survival in EC patients treated with CRT with or without surgery. Comorbidity information should be taken into consideration when individualized treatment decisions are made for EC patients.

Abbreviations

EC: 

Esophageal carcinoma

CRT: 

Chemoradiotherapy

OS: 

Overall survival

3DCRT: 

3-dimensional conformal radiation

IMRT: 

Intensity-modulated radiation

CAD: 

Coronary artery disease

AF: 

Atrial fibrillation

COPD: 

Chronic obstructive pulmonary disease

NSAIDs: 

Non-steroidal anti-inflammatory drugs

ACEi: 

Angiotensin-converting enzyme inhibitor

ARB: 

Angiotensin receptor blockers

HR: 

Hazard rate

CI: 

95% confidence interval

SCC: 

Squamous cell carcinoma

ADE: 

Adenocarcinoma

T3

Triiodothyronine

TR: 

Thyroid hormone nuclear receptors

KPS: 

Karnofsky performance scores

BMI: 

Body mass index

Declarations

Acknowledgements

We thank the data processing staff in our institution for their efforts in data collection.

Authors’ Affiliations

(1)
Departments of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
(2)
Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
(3)
Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
(4)
Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
(5)
Department of Radiation Oncology, Cancer Center, Sun Yat-Sun University, Guangzhou, China

References

  1. Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel Jr EL. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA. 2004;291:2441–7.View ArticlePubMedGoogle Scholar
  2. Koppert LB, Lemmens VE, Coebergh JW, Steyerberg EW, Wijnhoven BP, Tilanus HW, et al. Impact of age and co-morbidity on surgical resection rate and survival in patients with oesophageal and gastric cancer. Br J Surg. 2012;99:1693–700.View ArticlePubMedGoogle Scholar
  3. Backemar L, Djarv T, Wikman A, Johar A, Ross P, Lagergren P, et al. The role of diabetes and other co-morbidities on survival after esophageal cancer surgery in a population-based study. Am J Surg. 2013;206:539–43.View ArticlePubMedGoogle Scholar
  4. Skinner HD, McCurdy MR, Echeverria AE, Lin SH, Welsh JW, O’Reilly MS, et al. Metformin use and improved response to therapy in esophageal adenocarcinoma. Acta Oncol. 2013;52:1002–9.View ArticlePubMedGoogle Scholar
  5. Nguyen T, Khalaf N, Ramsey D, El-Serag HB. Statin Use is Associated with a Decreased Risk of Barrett’s Esophagus. Gastroenterology. 2014;147(2):314–23.View ArticlePubMedGoogle Scholar
  6. Sadeghi S, Bain CJ, Pandeya N, Webb PM, Green AC, Whiteman DC, et al. Aspirin, nonsteroidal anti-inflammatory drugs, and the risks of cancers of the esophagus. Cancer Epidemiol Biomarkers Prev. 2008;17:1169–78.View ArticlePubMedGoogle Scholar
  7. WMA Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects. [http://www.wma.net/en/30publications/10policies/b3/index.html]
  8. Pal SK, Hurria A. Impact of age, sex, and comorbidity on cancer therapy and disease progression. J Clin Oncol. 2010;28:4086–93.View ArticlePubMedGoogle Scholar
  9. Bhave PD, Goldman LE, Vittinghoff E, Maselli J, Auerbach A. Incidence, predictors, and outcomes associated with postoperative atrial fibrillation after major noncardiac surgery. Am Heart J. 2012;164:918–24.View ArticlePubMedPubMed CentralGoogle Scholar
  10. Ma JY, Wang Y, Zhao YF, Wu Z, Liu LX, Kou YL, et al. Atrial fibrillation after surgery for esophageal carcinoma: clinical and prognostic significance. World J Gastroenterol. 2006;12:449–52.View ArticlePubMedPubMed CentralGoogle Scholar
  11. Martinez-Iglesias O, Garcia-Silva S, Regadera J, Aranda A. Hypothyroidism enhances tumor invasiveness and metastasis development. PLoS One. 2009;4:e6428.View ArticlePubMedPubMed CentralGoogle Scholar
  12. Hercbergs AH, Ashur-Fabian O, Garfield D. Thyroid hormones and cancer: clinical studies of hypothyroidism in oncology. Curr Opin Endocrinol Diabetes Obes. 2010;17:432–6.View ArticlePubMedGoogle Scholar
  13. Nelson M, Hercbergs A, Rybicki L, Strome M. Association between development of hypothyroidism and improved survival in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg. 2006;132:1041–6.View ArticlePubMedGoogle Scholar
  14. Riesenbeck LM, Bierer S, Hoffmeister I, Kopke T, Papavassilis P, Hertle L, et al. Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib. World J Urol. 2011;29:807–13.View ArticlePubMedGoogle Scholar
  15. Cristofanilli M, Yamamura Y, Kau SW, Bevers T, Strom S, Patangan M, et al. Thyroid hormone and breast carcinoma. Primary hypothyroidism is associated with a reduced incidence of primary breast carcinoma. Cancer. 2005;103:1122–8.View ArticlePubMedGoogle Scholar
  16. Garfield D. Hypothyroidism promotes survival. Lancet Oncol. 2002;3:328.View ArticlePubMedGoogle Scholar
  17. Moeller LC, Fuhrer D. Thyroid hormone, thyroid hormone receptors, and cancer: a clinical perspective. Endocr Relat Cancer. 2013;20:R19–29.View ArticlePubMedGoogle Scholar
  18. Brown AR, Simmen RC, Simmen FA. The role of thyroid hormone signaling in the prevention of digestivesystem cancers. Int J Mol Sci. 2013;14:16240–57.View ArticlePubMedPubMed CentralGoogle Scholar
  19. Lee MS, Hsu CC, Wahlqvist ML, Tsai HN, Chang YH, Huang YC. Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. BMC Cancer. 2011;11:20.View ArticlePubMedPubMed CentralGoogle Scholar
  20. Feng Y, Ke C, Tang Q, Dong H, Zheng X, Lin W, et al. Metformin promotes autophagy and apoptosis in esophageal squamous cell carcinoma by downregulating Stat3 signaling. Cell Death Dis. 2014;5:e1088.View ArticlePubMedPubMed CentralGoogle Scholar
  21. Sadaria MR, Reppert AE, Yu JA, Meng X, Fullerton DA, Reece TB, et al. Statin therapy attenuates growth and malignant potential of human esophageal adenocarcinoma cells. J Thorac Cardiovasc Surg. 2011;142:1152–60.View ArticlePubMedGoogle Scholar
  22. Galipeau PC, Li X, Blount PL, Maley CC, Sanchez CA, Odze RD, et al. NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma. PLoS Med. 2007;4:e67.View ArticlePubMedPubMed CentralGoogle Scholar
  23. Choe KS, Cowan JE, Chan JM, Carroll PR, D’Amico AV, Liauw SL. Aspirin use and the risk of prostate cancer mortality in men treated with prostatectomy or radiotherapy. J Clin Oncol. 2012;30:3540–4.View ArticlePubMedPubMed CentralGoogle Scholar
  24. Yu O, Eberg M, Benayoun S, Aprikian A, Batist G, Suissa S, et al. Use of statins and the risk of death in patients with prostate cancer. J Clin Oncol. 2014;32:5–11.View ArticlePubMedGoogle Scholar
  25. Zhang ZJ, Li S. The prognostic value of metformin for cancer patients with concurrent diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2014;16(8):707–10.View ArticlePubMedGoogle Scholar

Copyright

© He et al.; licensee BioMed Central. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement